Eiger Biopharmaceuticals’ stock took a nosedive after it told investors it wouldn’t seek authorization from the Food and Drug Administration for its COVID-19 drug. It had asked the FDA to consider an EUA application based on data from a Phase 3 study that has assessed 11 possible treatments for COVID-19 that is being conducted in Brazil and Canada. (MarketWatch)

The Biden administration’s plans to revive Operation Warp Speed have stalled. With pandemic aid and funding halted in Congress, the initiative to fight future pandemics – initially dubbed ‘Project Covid Shield’ – has hit the skids. (POLITICO)

Eli Lilly lost its bid to cancel Teva migraine-drug patents before Emgality trial. Earlier this week, a Boston federal judge rejected Lilly’s request to invalidate three Teva Pharmaceuticals International GmbH patents in a long-running legal battle over the companies’ competing migraine medications. (Reuters)

Researchers found that LSD-based drugs seem to help mice with anxiety and depression — without the trip. “We found our compounds had essentially the same antidepressant activity as psychedelic drugs,” says Dr. Bryan Roth, an author of the study and a professor of pharmacology at UNC Chapel Hill School of Medicine. (NPR)

Medical advances have led to better treatment for Type 2 diabetes, but experts are calling for a solution to the disease that goes beyond medicine. The solution, they argue, lies in battling poverty, reducing pollution, improving the U.S. food system and developing cities that are walkable. (The New York Times)